BRAFV600E在甲状腺乳头状癌与桥本甲状腺炎相关性中的研究  

Study of BRAFV600E in the correlation between papillary thyroid carcinoma and Hashimoto＆#39;s thyroiditis

作　　者：于亚静[1] 杨彩哲[1] 刘明[1] 任力[1] 王良宸[1] 曹亚蕊 

机构地区：[1]空军总医院内分泌科,北京100142

出　　处：《国际内分泌代谢杂志》2014年第6期375-378,F0003,共5页International Journal of Endocrinology and Metabolism

摘　　要：目的 研究BRAFV600E在甲状腺乳头状癌与桥本甲状腺炎中的表达,探讨甲状腺乳头状癌与桥本甲状腺炎的相关性.方法 北京空军总医院2012年1月-2014年6月经病理证实的甲状腺石蜡标本,甲状腺乳头状癌40例、桥本甲状腺炎20例、甲状腺乳头状癌伴桥本甲状腺炎20例、甲状腺腺瘤20例,采用免疫组化（Envision法）检测BRAFV600E的表达并进行半定量分析,比较其在各组中的表达差异.结果 甲状腺乳头状癌BRAFV600E阳性率为77.5％ （31/40）,桥本甲状腺炎BRAFV600E阳性率为45.0％（9/20,P=0.012）.甲状腺乳头状癌伴桥本甲状腺炎的肿瘤组织区域BRAFV600E阳性率为70.0％（14/20）,与单纯甲状腺乳头状癌的阳性率差异无统计学意义（P=0.156）;而桥本甲状腺炎区域BRAFV600E阳性率为55％（11/20,P=0.527）,与单纯桥本甲状腺炎BRAFV600E的阳性率差异亦无统计学意义（P＞0.05）.甲状腺乳头状癌有转移者BRAFV600E阳性率（88.2％,15/17）高于甲状腺乳头状癌未转移者（69.5％,16/23,P=0.030）.甲状腺腺瘤中未检测到BRAFV600E.结论 甲状腺乳头状癌和桥本甲状腺炎均呈现较高的BRAFV600E突变率.Objective To explore the expression of BRAFV600E in papillary thyroid carcinoma and Hashimoto＇s thyroiditis,and investigate the correlation between papillary thyroid carcinoma and Hashimoto＇s thyroiditis.Methods The paraffin embedded tissue specimens of pathologically confirmed thyroid disease during 2012.1-2014.6 in the Air Force General Hospital were collected,including 40 cases of papillary thyroid carcinoma,20 cases of Hashimoto＇ s thyroiditis,20 cases of papillary thyroid carcinoma with Hashimoto＇s thyroiditis and 20 cases of thyroid adenoma.Immunohistochemistry （Envision method） was used to detect the expression of BRAFV600E and semi quantitative analysis was used to compare the difference of different thyroid diseases.Results The positive rate of BRAFV600E was 77.5% （31/40） in papillary thyroid carcinoma and 45% （9/20） in Hashimoto＇ s thyroiditis （P =0.012）.In papillary thyroid carcinoma with Hashimoto＇s thyroiditis,the positive rate of BRAFV600E in thyroid papillary carcinoma tissue was 70.0% （14/20）,which was not different from thyroid papillary carcinoma （P =0.156） ; and the positive rate of BRAFV600E in Hashimoto＇s thyroiditis tissue was 55.0% （11/20）,which was not different from Hashimoto＇s thyroiditis（P =0.527）.The positive rate of BRAFVE600 in metastatic papillary thyroid carcinoma was 88.2% （15/17）,which was higher than that in papillary thyroid carcinoma without metastasis （69.5%,16/23,P =0.030）.There was no expression of BRAFV600E in thyroid adenoma.Conclusion Papillary thyroid carcinoma and Hashimoto＇s thyroiditis have a higher BRAFV600E mutation rate.

关 键 词：甲状腺乳头状癌 桥本甲状腺炎 

分 类 号：R736.1[医药卫生—肿瘤]